2.13
+0.08(+3.90%)
Currency In USD
| Previous Close | 2.05 |
| Open | 2.15 |
| Day High | 2.19 |
| Day Low | 2.1 |
| 52-Week High | 3.08 |
| 52-Week Low | 0.6 |
| Volume | 216,452 |
| Average Volume | 558,829 |
| Market Cap | 173.94M |
| PE | -3.87 |
| EPS | -0.55 |
| Moving Average 50 Days | 1.72 |
| Moving Average 200 Days | 1.18 |
| Change | 0.08 |
If you invested $1000 in I-Mab (IMAB) since IPO date, it would be worth $170.4 as of July 12, 2025 at a share price of $2.13. Whereas If you bought $1000 worth of I-Mab (IMAB) shares 3 years ago, it would be worth $203.24 as of July 12, 2025 at a share price of $2.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
GlobeNewswire Inc.
Jul 02, 2025 3:15 PM GMT
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
GlobeNewswire Inc.
Jun 30, 2025 8:01 PM GMT
Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ROCKVILLE, MD, June 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global
I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
GlobeNewswire Inc.
Jun 26, 2025 10:30 AM GMT
71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Upd